ArticlePharmacoEconomics - open2018

Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders' Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL).

Martina Garau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.